General approach to the treatment of diabetes mellitus

Joslin's Diabetes Mellitus: Fourteenth Edition

Volumn , Issue , 2011, Pages 587-596

  Cooppan, Ramachandiran ^a,b  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84971009669     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (41)

1. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin dependent diabetes mellitus. Diabetes Control and Complications Trial Research Group. . Engl J Med 1993;329:977-986.
2. Ohkubo Y, Kishikawa H, Arak E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non insulin dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995;28:103-117.
3. Intensive blood glucose control with sulfonylureas or insulin compared with conventional treatment and the risk of complications in patients with type 2 diabetes (UKPDS 33): UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352:837-853.
4. Shichiri M, Ohkubo Y, Kishikawa H, et al. Long term results of the Kumamoto study in optimal diabetes control in type 2 diabetic patients. Diabetes Care 2000;23[Suppl 2]:B21-B29.
5. Javitt JC, Chiang Y. Economic impact of diabetes. In: National Diabetes Data Group, eds. Diabetes in America. Bethesda, MD: National Institute of Diabetes and Kidney Diseases, 1995:601-611; NIH publication 95-1468.
6. Yudkin JS. Insulin for the world's poorest nations. Lancet 2000;355:919-921.
7. American Diabetes Association. Report of the Expert Committee of the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 2000;23[Suppl 1]: S4-S19.
8. McCance DR, Hanson RL, Charles MA, et al. Comparison of tests for glycated hemoglobin and fasting and two hour plasma glucose concentrations as diagnostic methods for diabetes. BMJ 1994;308:1323-1328.
9. Engelgau MM, Thompson TJ, Herman WH, et al. Comparison of fasting and 2-hour glucose and HbA1c levels for diagnosing diabetes: diagnostic criteria and performance revisited. Diabetes Care 1997;20:785-791. 10.Alberti KGGM. The clinical implications of impaired glucose tolerance. Diabet Med 1996;13:927-937.
10. Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. The Decode Study group. European Diabetes Epidemiology Group. Diabetes Epidemiology: collaborative analysis of diabetes criteria in Europe. Lancet 1999;354:617-621.
11. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE Study and MICR-HOPE Substudy: Heart Outcomes Prevention Evaluation Study Investigators. Lancet 2000;355:253-259.
12. Gress TW, Nieto FJ, Shahar E, et al. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Engl J Med 2000;342:905-912.
13. Knowler WC, Pettitt DJ, Savage PJ, et al. Diabetes incidence in Pima Indians: contribution of obesity and paternal diabetes. Am J Epidemiol 1981;113:114-156.
14. Diehl AK, Stern MP. Special health problems of Mexican-Americans: obesity, gall bladder disease, diabetes mellitus and cardiovascular disease. Adv Intern Med 1989;34:13-56.
15. Fujimoto WF. Background and recruitment data for the US Diabetes Prevention Program. Diabetes Care 2000;23[Suppl 2]:B11-B13.
16. Kenny SJ, Aubert RE, Geiss LS. Prevalence and incidence of non-insulin-dependent diabetes. In: Harris MI, Cowie CC, Stern MJ, eds. Diabetes in America, 2nd ed. Bethesda, MD: National Institute of Diabetes and Kidney Diseases, 1995: 47-67; NIH publication 95-1468.
17. Minaker KL. What diabetologists should know about elderly patients. Diabetes Care 1990;13[Suppl 2]:34-46.
18. Thivolet C, el Farkh J, Petiot A, et al. Measuring vibration sensations with a graduated tuning fork: a simple and reliable means to detect diabetic patients at risk for neuropathic foot ulceration. Diabetes Care 1990;13:1077-1080.
19. Dyck PJ, Melton LJ 3rd, O'Brien PC, et al. Approaches to improve epidemiological studies of diabetic neuropathy: insights form the Rochester Diabetic Neuropathy Study. Diabetes 1997;46[Suppl 2]:S5-S8.
20. Perkins BA, Olaleye D, Zinman B, et al. Simple screening tests for peripheral neuropathy in the diabetes clinic. Diabetes Care 2001;24:250-256.
21. Haffner SM, Lehto S, Ronnemaa T, et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in non-diabetic subjects with and without prior myocardial infarction. . Engl J Med 1998;339:229-234.
22. Mogensen CE. Prediction of clinical diabetic nephropathy in IDDM patients: alternatives to microalbuminuria? Diabetes 1990;39:761-767.
23. Mogensen CE. Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. . Engl J Med 1984;310:356-360.
24. Ziegler AG, Ziegler R, Vardi P, et al. Life-table analysis of progression to diabetes of anti-insulin autoantibody-positive relatives of individuals with type I diabetes. Diabetes 1989;38:1320-1325.
25. Krischer JP, Schatz D, Riley WJ, et al. Insulin and islet cell autoantibodies as time-dependent covariates in the development of insulin dependent diabetes. . Clin Endocrinol Metab 1993;77:743-479.
26. Janand-Delenne B, Savin B, Habib G, Bory M, et al. Silent myocardial ischemia in patients with diabetes: who to screen. Diabetes Care 1999;22: 1396-1400.
27. Physician's guide to insulin-dependent (type 1) diabetes: diagnosis and treatment. Alexandria, VA: American Diabetes Association, 1988:18.
28. American Diabetes Association. Standards of medical care in diabetes. Diabetes Care 2004;[Suppl 1]:S19.
29. American Diabetes Association. Tests of glycemia in diabetes. Diabetes Care 2000; 23[Suppl 1]:560-582.
30. Jovanovic-Peterson L, Peterson CM, Dudley JD, et al. Identifying sources of error in self monitoring blood glucose. Diabetes Care 1988;11:791-794.
31. Allen BT, Delong ER, Feusser JR. Impact of glucose self monitoring on non insulin treated patients with type II diabetes mellitus: randomized controlled trial comparing blood and urine testing. Diabetes Care 1990;13:1044-1050.
32. Bunn HF, Haney DN, Gabbay KH, et al. Further identification of the nature and linkage of the carbohydrate in hemoglobin A1c. Biochem Biophys Res Comm 1975;67:103-109.
33. Rahbar S. An abnormal hemoglobin in red cells of diabetics. Clin Chim Acta 1968;22: 296-298.
34. Koenig RJ, Peterson CM, Jones RL. Correlation of glucose regulation and hemoglobin A1c in diabetes mellitus. . Engl J Med 1976;295:417-420.
35. Schnedl WJ, Krause R, Halwach-Baumann G, et al. Evaluation of HbA1c determination methods in patients with hemoglobinopathies. Diabetes Care 2000;23:339-344.
36. Brewer W, Chase HP, Owen S, et al. Slicing the pie. Correlating HbA1c values with average glucose values in a pie-chart form. Diabetes Care 1998;21:209-212.
37. American Diabetes Association. Continuous subcutaneous insulin infusion. Diabetes Care 2000;23[Suppl 1]:S90.
38. Genuth S. Insulin use in NIDDM. Diabetes Care 1990;13:1240-1264. 48a. Riddle MC, Rosenstock J, Gerich J, on behalf of the insulin glargine 2002 study investigators. Randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003;26:3080-3086.
39. Riddle MC. Evening insulin. Diabetes Care 1991;13:676-686.
40. Nesto RW. Screening for asymptomatic coronary disease in diabetes. Diabetes Care 1999;22:1393-1395.
41. Watkins K, Connell CM, Fitzgerald JT, et al. Effect of adults' self-regulation of diabetes on quality-of-life outcomes. Diabetes Care 2000;23:1511-1515.